Edition:
India

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

17.50USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$17.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
775,833
52-wk High
$18.75
52-wk Low
$7.15

Latest Key Developments (Source: Significant Developments)

Array Biopharma Reports Q3 Loss Per Share $0.11
Wednesday, 9 May 2018 

May 9 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2018.Q3 LOSS PER SHARE $0.11.Q3 REVENUE $66.4 MILLION.Q3 REVENUE VIEW $31.7 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $440 MILLION.  Full Article

Aslan Pharmaceuticals buys full global commercial rights for Varlitinib
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA.ARRAY BIOPHARMA INC HAS GRANTED ASLAN FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE VARLITINIB​.ASLAN WILL MAKE AN UPFRONT PAYMENT OF $12 MILLION TO ARRAY ON SIGNATURE AND FURTHER PAYMENT OF UP TO $12 MILLION WITHIN NEXT 12 MONTHS​.ASLAN WILL MAKE UPFRONT PAYMENT TOGETHER WITH UP TO US$30 MILLION OF DEVELOPMENT AND US$75 MILLION OF COMMERCIAL MILESTONES.  Full Article

Array Biopharma Contributes Rights And Assets Related To Arry-797 Drug Program To Yarra Therapeutics
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA SAYS ON DEC 21, CO CONTRIBUTED CERTAIN RIGHTS AND ASSETS RELATED TO ARRY-797 DRUG PROGRAM TO YARRA THERAPEUTICS - SEC FILING.ARRAY BIOPHARMA SAYS FORMED YARRA TO FURTHER DEVELOP, COMMERCIALIZE THERAPEUTICS TARGETED TOWARDS RARE DISEASES, INCLUDING ARRY-797 DRUG PROGRAM.ARRAY BIOPHARMA - YARRA WILL BE LED BY BRYAN STUART, WHO WILL SERVE AS YARRA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.  Full Article

Array BioPharma Announces Strategic Collaboration With Pfizer
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER.ARRAY BIOPHARMA SAYS UNDER COLLABORATION AGREEMENT, TRIAL WILL BE SPONSORED AND FUNDED BY PFIZER, WITH ARRAY PROVIDING BINIMETINIB SUPPLY.ARRAY BIOPHARMA - PHASE 1B CLINICAL STUDY IS EXPECTED TO BEGIN BY Q3 2018.ARRAY BIOPHARMA - ENTERED INTO CLINICAL TRIAL AGREEMENT WITH PFIZER TO INVESTIGATE SAFETY, EFFICACY OF SEVERAL NOVEL ANTI-CANCER COMBINATIONS.  Full Article

Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION.ARRAY BIOPHARMA SAYS ‍2024 NOTES WILL MATURE ON DEC 1, 2024​ - SEC FILING.ARRAY - ALSO ISSUED AGGREGATE OF ABOUT 7.96 MILLION SHARES OF CO'S COMMON STOCK IN EXCHANGE OF $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020​.ARRAY BIOPHARMA - ‍2024 NOTES TO BEAR INTEREST AT 2.625% PAYABLE SEMIANNUALLY IN ARREARS ON JUNE 1 & DEC 1 OF EACH YEAR, BEGINNING JUNE 1, 2018​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Array Biopharma Inc :ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018.Q1 LOSS PER SHARE $0.22.Q1 REVENUE $29.7 MILLION VERSUS I/B/E/S VIEW $33.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.‍INCREASE IN QTRLY NET LOSS WAS PRIMARILY DUE TO A DECREASE IN REIMBURSEMENT REVENUE FROM NOVARTIS​.‍INCREASE IN QTRLY NET LOSS WAS ALSO PRIMARILY DUE TO A DECREASE IN NON-RECURRING COSTS FOR COMMERCIAL DRUG SUPPLY FROM NOVARTIS​.  Full Article

Array Biopharma reports financial results for Q2 of fiscal 2017
Thursday, 9 Feb 2017 

Array Biopharma Inc - : Array Biopharma reports financial results for the second quarter of fiscal 2017 . Q2 loss per share $0.14 . Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S . Cash, cash equivalents and marketable securities as of December 31, 2016 were $214.8 million . Says revenue for q2 of fiscal 2017 was $44.5 million, compared to $39.3 million for prior sequential quarter .Says revenue for q2 of fiscal 2017 increased $9.1 million compared to same quarter of fiscal 2016.  Full Article

Array BioPharma Q1 revenue $39.3 mln
Tuesday, 1 Nov 2016 

Array BioPharma Inc : Array BioPharma Inc - Columbus met its primary endpoint in study . Array BioPharma - reimbursement revenue from Novartis was about $129 million for previous 12 months, of which $31.3 million was recorded over past quarter . Array BioPharma reports financial results for the first quarter of fiscal 2017 . Q1 loss per share $0.20 . Q1 revenue $39.3 million versus Thomson Reuters I/B/E/S view $32.5 million .Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Array Biopharma prices public offering at $6.25 per share
Wednesday, 28 Sep 2016 

Array Biopharma Inc : Array Biopharma announces pricing of public offering of common stock .Says public offering of 18.4 million common shares priced at $6.25 per share.  Full Article

BRIEF-Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald

* ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING